TwentyTwentyTweets
Tweets by 2020health-
Join 7,195 other subscribers
-
Recent Posts
Pages
Tag Archives: NICE
‘Parity of esteem’ – a society free from stigma and discrimination
Guest Blog from the Mental Health Foundation The Select Committee on Health’s enquiry into children and young people’s mental health and the launch of the NHS England Mental Health Task Force are welcome developments in a year that has seen … Continue reading
Equal treatment for Depression needs legal force
2020Health claims legal enforcement of key measures are necessary to ensure ‘parity of esteem’ and for Britain to tackle depression in the workplace. 2020Health has today published a new report, ‘Whole in One – Achieving equality of status, access and resources … Continue reading
Threats to Mankind from Drug Resistant Bacteria and Viruses
The risk of an end to the human race may sound like science fiction. However, there are only a small number of threats that could theoretically lead to the extinction of mankind. The four main concerns that most experts share … Continue reading
Posted in Business, David Cameron, Drugs, Global Health, GPs, International, Most Significant, NHS, Pharma, Public Health, Rare conditions, Research, Vaccination
Tagged 2020health, AIDS, amoxicillin, Antibacterial, antibiotics, antiviral, Augmentin, bacteria, bacterial susceptibility, beta-lactam, beta-lactamase, bureaucracy, carpenem, cephalosporin, Ebola, end of mankind, Gilead, hepatitis, Hospitals, Human, hygiene, isolation, monobactam, NICE, pathogen, penicillin, plague, PPRS, prescribing, prevention, Prime Minister, Pseudomonas, R & D, R&D, rabies, Research, Research and development, resistance, sofosbuvir, Sovaldi, vaccine, virus, WHO
Comments Off on Threats to Mankind from Drug Resistant Bacteria and Viruses
Medical advisory body “NICE” should not spend too much time valuing drugs.
The UK National Institute for Health and Care Excellence (“NICE”) is currently holding a public consultation over its proposals for evaluating drugs. Drugs that are approved by NICE automatically become available for doctors to prescribe under the NHS throughout England … Continue reading
Posted in Business, CCGs, Commissioning, Department of Health, Drugs, Elderly, equality, Genetics, GPs, Health and Wellbeing, Health Bill, Health reform, Inequality, Innovation, Jeremy Hunt, NHS, NHS reforms, Patients, Pharma, Policy, Public Health, Research, Technology, Uncategorized, Wellbeing
Tagged 2020health, Clinical Commissioning Group, Commissioning, Department of Health, dose, elderly, General practitioner, government, GP, GPs, health, Health Bill, innovation, Jeremy Hunt, medicine, Medicines and Healthcare products Regulatory Agency, MHRA, National Health Service, National Institute for Health and Care Excellence, NHS, NICE, Old age, patient, Patients, pharmaceutical, PPRS, pricing, Proportionate QALY, Public Health, QALY, R&D, Research, value-based, value-based pricing
Leave a comment
Guest Blogspot: Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry.
The UK Government and the pharmaceutical industry shared many objectives throughout the recent drug pricing negotiations. For example, there was always broad agreement that: The total future drug bill needed to be affordable in the context of other spending in … Continue reading
Posted in Andrew Lansley, Business, Cancer, Department of Health, Drugs, Innovation, Jeremy Hunt, NHS, Patients, Pharma, Research, Smoking ban
Tagged 2020health, Andrew Lansley, Department of Health, Drugs, government, innovation, Jeremy Hunt, National Health Service, NHS, NICE, parallel export, parallel imporrt, patient, Patient Access Scheme, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing, VBP
1 Comment
Pharmaceutical companies must be free to determine their own research priorities: Lessons from Alzheimer’s Disease
Guest blog post from Barbara Arzymanow, Independent Healthcare Consultant Sir David Jack (1924-2011), one of history’s greatest pharmaceutical R&D directors under whom many important drugs were discovered, once told me that neither governments nor companies should overrule senior R&D management. … Continue reading
Posted in Business, Drugs, Innovation
Tagged acetylcholine, acetylcholinesterase, Alzheimer's, block-buster, British Biotech, C1-inh, cholinesterase, David Jack, glutamate, hub, innovation, marimastat, medicine, mental health, Neurochem, NICE, NMDA, pharmaceutical, R&D, Research, Sir David Jack
Leave a comment
Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.
David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading
Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care
Tagged 2020health, block-buster, competition, David Cameron, demand, Department of Health, drug pricing system, Drugs, elderly, GP, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, parallel exports, parallel imports, patient, Patients, pharmaceutical, Philosophy and Economics, Politics, PPE, PPRS, pricing, quality of life, R&D, reference price, Research, value-based, value-based pricing, VBP
Leave a comment
Guest Blogspot: A wrong decision on UK drug pricing could seriously undermine all the good work that HM Treasury and the Department for Business, Innovation and Skills have done to encourage the UK pharmaceutical industry.
The recent local elections highlight the political dangers ahead. The current UK coalition government has lost popularity through decisions that do not all relate to austerity measures. Shortly after the General Election Andrew Lansley’s plans to increase the say of … Continue reading
Posted in Andrew Lansley, Business, Department of Health, Drugs, Election, Global Health, Health Bill, NHS, Patient choice, Patients, Pharma, Policy, Research, Technology
Tagged 2020health, Andrew Lansley, AstraZeneca, Department of Health, Drugs, GlaxoSmithKline, GSK, health, Health Bill, innovation, medicine, National Health Service, NHS, NICE, patient, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
Leave a comment
Guest Blogspot: Pharmaceutical R & D – the value of radical innovation versus incremental progress
What we really want is affordable products that benefit patients, whether or not they are “innovative” in the usual sense of the word. Scientific innovation is not a medical end in itself. The ultimate aim of pharmaceutical R&D is to … Continue reading
Posted in Business, competition, Department of Health, Drugs, Emerging technologies, Finance, Healthcare, Innovation, NHS, Patients, Pharma, Policy, Research, Technology, Uncategorized
Tagged 2020health, Alderlin, angina, atenolol, beta-blocker, cimetidine, competition, David Jack, definition of innovation, Department of Health, Drugs, Eraldin, government, heart drug, incremental, Inderal, innovation, innovative, James Black, medicine, Michael Rawlins, National Health Service, NHS, NICE, patient, Patients, pharmaceutical, practolol, pricing, pronethalol, propranolol, R&D, ranitidine, Research, Sir David Jack, Sir James Black, Sir Michael Rawlins, Tagamet, Tenormin, ulcer drug, value-based, value-based pricing, Zantac
Leave a comment
The Health and Social Care Bill: Final Stages in Parliament
With opposition to the Health and Social Care Bill having reached new heights, we must look behind the rhetoric and remember basic principles. The most important point to remember is that the NHS exists to provide the best possible, affordable … Continue reading
Posted in Andrew Lansley, Business, Commissioning, competition, David Cameron, Department of Health, GPs, Health Bill, Hospitals, Inequality, NHS, Patient choice, Patients
Tagged 2020health, Andrew Lansley, Bevan, BMA, bureaucracy, Commissioning, competition, David Cameron, Department of Health, efficiency, government, GP, GPs, health, Health Bill, inaccurate media, National Health Service, NHS, NICE, Nye Bevan, Old age, patient, Patients, Responsibility in healthcare
Leave a comment
2020health's Blog 
You must be logged in to post a comment.